



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Sapropterin Dipharma

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
T/0009	Transfer of Marketing Authorisation	19/12/2022	30/01/2023	SmPC, Labelling and PL	
IB/0008	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	13/12/2022	30/01/2023	SmPC and PL	

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0007/G	<p>This was an application for a group of variations.</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p> <p>B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)</p>	17/11/2022	30/01/2023	SmPC	Product information section 6.3 is updated to reflect the shelf-life extension of the finished product Sapropterin Dipharma 100 mg soluble tablets (EU/1/21/1620/001-002), Sapropterin Dipharma 100 mg powder for oral solution (EU/1/21/1620/003) and Sapropterin Dipharma 500 mg powder for oral solution (EU/1/21/1620/004) as packaged for sale from 24 months to 36 months.
IA/0006	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	16/09/2022	n/a		
IB/0005	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	26/08/2022	n/a		
IAIN/0004/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -</p>	20/06/2022	30/01/2023	Annex II and PL	

	Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
IB/0001	C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication	08/04/2022	05/05/2022	SmPC and PL	
IB/0002	B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method	01/04/2022	n/a		
IA/0003	B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold	14/03/2022	n/a		